Premium
A case report of acquired hemophilia following COVID‐19 vaccine
Author(s) -
Radwi Mansoor,
Farsi Sara
Publication year - 2021
Publication title -
journal of thrombosis and haemostasis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.947
H-Index - 178
eISSN - 1538-7836
pISSN - 1538-7933
DOI - 10.1111/jth.15291
Subject(s) - medicine , partial thromboplastin time , vaccination , covid-19 , von willebrand disease , malignancy , immunology , pediatrics , von willebrand factor , dermatology , disease , infectious disease (medical specialty) , platelet
Acquires hemophilia A (AHA) is rare bleeding condition commonly associated with malignancy, autoimmune disease, or pregnancy. We report a case of a 69‐year‐old gentleman who developed bleeding symptoms after receiving COVID‐19 vaccine. Laboratory testing showed isolated prolongation of the activated partial thromboplastin time, and normal von Willebrand factor. Further testing confirmed the presence of factor VIII inhibitor. To date, no cases of AHA have been reported after exposure to COVID‐19 vaccine. There have been two cases of AHA following seasonal flu and H1N1 vaccination, as well as two cases of AHA following COVID‐19 infection. We present a summary of these cases and review of literature of autoimmune reactions following vaccination.